Targeting WFS1 overcomes KRAS(G12D) dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.
Blocking a newly identified resistance mechanism could help KRAS-targeted pancreatic cancer drugs work longer, addressing a key obstacle to treating this deadly cancer.
This preclinical study identifies WFS1 as a key mediator of adaptive resistance to KRAS(G12D) inhibition in pancreatic cancer, demonstrating that co-targeting WFS1 can overcome this resistance. The finding is potentially important given that KRAS G12D inhibitors are now entering clinical trials for pancreatic cancer.
What the study was
- Study design
- Preclinical mechanistic study — in vitro and likely in vivo model
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- NPJ Precision Oncology
Why it surfaced
WFS1 as a co-target for KRAS G12D resistance in pancreatic cancer is mechanistically interesting. Score capped at 5/10 per non-human study rule (preclinical only). Pancreatic cancer has very high unmet need (+1 pop). Score: novelty 2, relevance 2, design 0 (preclinical), pop 1.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.